Prolacta Bioscience, the world’s leading hospital provider of 100% human milk-based nutritional products, today announced the U.S. Food and Drug Administration (FDA) has approved Surgifort® human milk fortifier (human pasteurized) for term infants (> 37 weeks) following corrective surgery for the gastrointestinal disorder gastroschisis.
Surgifort fortifier is the latest addition to Prolacta’s line of human milk-based nutritional products, and it is the first fortifier indicated for use in term babies.
Gastroschisis is a birth defect where the intestines, and sometimes other organs, protrude through the abdominal wall. Similar to premature infants, term infants recovering from corrective gastroschisis surgery require high macronutrient intake for optimal growth.1 Surgifort fortifier is specifically formulated to deliver optimal protein and calories to promote growth. When Surgifort fortifier is mixed with term human milk, and given at an appropriate volume, clinicians can achieve nutrition that is within the recommendations established by the National Academy of Medicine.2
